Runben Biotechnology Co

Runben Biotechnology Co FCF/Debt

The Free Cash Flow to Debt Ratio of Runben Biotechnology Co (603193.SS) as of Oct 20, 2026 is 12,909.41 %. In the previous year, Free Cash Flow to Debt Ratio was 11,696.77 % — a change of 10.37% (higher).

FCF/Debt

12,909.41 %

YoY

10.37%

Last updated:

Free Cash Flow to Debt Ratio of Runben Biotechnology Co is 2024 12,909.41 % . Free Cash Flow to Debt Ratio of Runben Biotechnology Co was 2023 11,696.77 % . It decreases by 10.37% higher compared to the previous year.

The Runben Biotechnology Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2021
-129.81 CNY
Jan 1, 2022
1,576.57 CNY
Jan 1, 2023
11,696.77 CNY
Jan 1, 2024
12,909.41 CNY
The Runben Biotechnology Co FCF/Debt history
YEARFCF/DebtYoY
12,909.41 %+10.37%
11,696.77 %+641.91%
1,576.57 %-1,314.52%
-129.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sale of mosquito repellent, baby care, and personal care products. The company's main product categories include electric mosquito repellent liquid, DEET mosquito repellent liquid, lipstick, face cream, facial cleanser, and skin care cream, which are sold via online direct sales, online platform distribution, and online platform agency sales. These products target domestic consumers in China, with the firm focusing on internet-based sales channels to reach its customer base. The company's product portfolio spans mosquito repellent solutions, baby care items, and essential oil products, with key offerings such as DEET mosquito repellent liquid and electric mosquito repellent liquid driving sales. Baby care products and personal care items like lipstick and face cream are distributed through online platforms, leveraging digital channels to serve the domestic market. Runben Biotechnology emphasizes direct consumer engagement through e-commerce platforms to facilitate product distribution. Runben Biotechnology's revenue streams are derived from the sale of its core product lines, including mosquito repellent products, baby care products, and essential oil products. The firm's domestic market focus ensures that its products, such as facial cleanser and skin care cream, are tailored to local consumer preferences. Online sales models, including direct online sales and platform agency sales, form the primary channel for product delivery to end-users. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Runben Biotechnology Co stock

Free Cash Flow to Debt Ratio of Runben Biotechnology Co is 12,909.41 % in 2024.

Free Cash Flow to Debt Ratio of Runben Biotechnology Co changed from 11,696.77 % to 12,909.41 %, representing a 10.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Runben Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co